PTC Receives $1.5 Million Grant From Muscular Dystrophy Association

PTC Therapeutics, Inc (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, announced that the company has been awarded a $1.5 million grant from the Muscular Dystrophy Association (MDA). The award will be utilized to fund the development of PTC124 for the treatment of Duchenne muscular dystrophy (DMD) due to a nonsense mutation in the dystrophin gene. It is estimated that 15 percent of the cases of DMD are due to a nonsense mutation.

Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=23231)